Circulating Exosomes and Exosomal Micrornas As Biomarkers in Gastrointestinal Cancer Publisher Pubmed

Summary: A review suggests exosome miRNAs in body fluids may detect GI cancers early, offering non-invasive testing. #CancerResearch #Biomarkers

Nedaeinia R^{1, 2} ; Manian M³ ; Jazayeri MH³ ; Ranjbar M⁴ ; Salehi R⁵ ; Sharifi M⁵ ; Mohaghegh F⁶ ; Goli M⁷ ; Jahednia SH⁸ ; Avan A⁹ ; Ghayourmobarhan M^{9, 10}
Source: Cancer Gene Therapy Published:2017

Abstract

The most important biological function of exosomes is their possible use as biomarkers in clinical diagnosis. Compared with biomarkers identified in conventional specimens such as serum or urine, exosomal biomarkers provide the highest amount of sensitivity and specificity, which can be attributed to their excellent stability. Exosomes, which harbor different types of proteins, nucleic acids and lipids, are present in almost all bodily fluids. The molecular constituents of exosomes, especially exosomal proteins and microRNAs (miRNAs), are promising as biomarkers in clinical diagnosis. This discovery that exosomes also contain messenger RNAs and miRNAs shows that they could be carriers of genetic information. Although the majority of RNAs found in exosomes are degraded RNA fragments with a length of <200 nucleotides, some full-length RNAs might be present that may affect protein production in the recipient cell. In addition, exosomal miRNAs have been found to be associated with certain diseases. Several studies have pointed out miRNA contents of circulating exosomes that are similar to those of originating cancer cells. In this review, the recent advances in circulating exosomal miRNAs as biomarkers in gastrointestinal cancers are discussed. These studies indicated that miRNAs can be detected in exosomes isolated from body fluids such as saliva, which suggests potential advantages of using exosomal miRNAs as noninvasive novel biomarkers. © The Author(s) 2017.